I. B. Bayer-garner, R. D. Sanderson, M. V. Dhodapkar, R. B. Owens, and C. S. Wilson, Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions, Modern Pathology, vol.14, issue.10, pp.1052-1060, 2001.
DOI : 10.1038/modpathol.3880435

M. Belting, Heparan sulfate proteoglycan as a plasma membrane carrier, Trends in Biochemical Sciences, vol.28, issue.3, pp.145-51, 2003.
DOI : 10.1016/S0968-0004(03)00031-8

M. Bernfield, M. Gotte, P. W. Park, O. Reizes, M. L. Fitzgerald et al., Functions of Cell Surface Heparan Sulfate Proteoglycans, Annual Review of Biochemistry, vol.68, issue.1, pp.729-77, 1999.
DOI : 10.1146/annurev.biochem.68.1.729

K. L. Carraway, J. L. Weber, M. J. Unger, J. Ledesma, N. Yu et al., Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases, Nature, vol.387, issue.6632, pp.512-518, 1997.
DOI : 10.1038/387512a0

A. Citri, K. B. Skaria, and Y. Yarden, The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Experimental Cell Research, vol.284, issue.1, pp.54-65, 2003.
DOI : 10.1016/S0014-4827(02)00101-5

V. Costes, V. Magen, E. Legouffe, L. Durand, P. Baldet et al., The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens, Human Pathology, vol.30, issue.12, pp.1405-1416, 1999.
DOI : 10.1016/S0046-8177(99)90160-0

J. R. Couchman, Syndecans: proteoglycan regulators of cell-surface microdomains?, Nature Reviews Molecular Cell Biology, vol.4, issue.12, pp.926-963, 2003.
DOI : 10.1038/nrm1257

D. Vos, J. Couderc, G. Tarte, K. Jourdan, M. Requirand et al., Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays, Blood, vol.98, issue.3, pp.771-780, 2001.
DOI : 10.1182/blood.V98.3.771

P. W. Derksen, R. M. Keehnen, L. M. Evers, M. H. Van-oers, M. Spaargaren et al., Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma, Blood, vol.99, issue.4, pp.1405-1415, 2002.
DOI : 10.1182/blood.V99.4.1405

M. V. Dhodapkar, T. Kelly, A. Theus, A. B. Athota, B. Barlogie et al., Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma, British Journal of Haematology, vol.99, issue.2, pp.368-71, 1997.
DOI : 10.1046/j.1365-2141.1997.3893203.x

R. C. Harris, E. Chung, and R. J. Coffey, EGF receptor ligands, Experimental Cell Research, vol.284, issue.1, pp.2-13, 2003.
DOI : 10.1016/S0014-4827(02)00105-2

J. Hendriks, L. Planelles, J. De-jong-odding, G. Hardenberg, S. T. Pals et al., Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation, Cell Death and Differentiation, vol.26, issue.6, pp.637-685, 2005.
DOI : 10.1038/sj.cdd.4401647

S. Higashiyama, J. A. Abraham, and M. Klagsbrun, Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate, The Journal of Cell Biology, vol.122, issue.4, pp.933-973, 1993.
DOI : 10.1083/jcb.122.4.933

T. Holbro, G. Civenni, and N. E. Hynes, The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003.
DOI : 10.1016/S0014-4827(02)00099-X

N. E. Hynes and H. A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors, Nature Reviews Cancer, vol.7, issue.5, pp.341-54, 2005.
DOI : 10.1021/jm00130a020

K. Ingold, A. Zumsteg, A. Tardivel, B. Huard, Q. G. Steiner et al., Identification of proteoglycans as the APRIL-specific binding partners, The Journal of Experimental Medicine, vol.103, issue.9, pp.1375-83, 2005.
DOI : 10.1002/eji.1830221136

C. P. Klerk, S. M. Smorenburg, H. M. Otten, A. W. Lensing, M. H. Prins et al., The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy, Journal of Clinical Oncology, vol.23, issue.10, pp.2130-2135, 2005.
DOI : 10.1200/JCO.2005.03.134

A. Kumar, T. Loughran, M. Alsina, B. G. Durie, and B. Djulbegovic, Management of multiple myeloma: a systematic review and critical appraisal of published studies, The Lancet Oncology, vol.4, issue.5, pp.293-304, 2003.
DOI : 10.1016/S1470-2045(03)01077-5

W. M. Liu, R. Mei, X. Di, T. B. Ryder, E. Hubbell et al., Analysis of high density expression microarrays with signed-rank call algorithms, Bioinformatics, vol.18, issue.12, pp.1593-1602, 2002.
DOI : 10.1093/bioinformatics/18.12.1593

J. A. Loeb and G. D. Fischbach, ARIA can be released from extracellular matrix through cleavage of a heparin-binding domain, The Journal of Cell Biology, vol.130, issue.1, pp.127-162, 1995.
DOI : 10.1083/jcb.130.1.127

K. Mahtouk, D. Hose, T. Reme, J. De-vos, M. Jourdan et al., Oncogene, 2005.

K. Mahtouk, M. Jourdan, J. De-vos, C. Hertogh, G. Fiol et al., An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis, Blood, vol.103, issue.5, pp.1829-1866, 2004.
DOI : 10.1182/blood-2003-05-1510

URL : https://hal.archives-ouvertes.fr/inserm-00130207

J. Moreaux, E. Legouffe, E. Jourdan, P. Quittet, T. Reme et al., BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone, Blood, vol.103, issue.8, pp.3148-57, 2004.
DOI : 10.1182/blood-2003-06-1984

URL : https://hal.archives-ouvertes.fr/inserm-00129502

R. S. Mummery and C. C. Rider, Characterization of the Heparin-Binding Properties of IL-6, The Journal of Immunology, vol.165, issue.10, pp.5671-5680, 2000.
DOI : 10.4049/jimmunol.165.10.5671

A. C. Rapraeger, Syndecan-Regulated Receptor Signaling, The Journal of Cell Biology, vol.19, issue.5, pp.995-1003, 2000.
DOI : 10.1016/S0955-0674(98)80038-0

R. D. Sanderson, Y. Yang, L. J. Suva, and T. Kelly, Heparan sulfate proteoglycans and heparanase???partners in osteolytic tumor growth and metastasis, Matrix Biology, vol.23, issue.6, pp.341-52, 2004.
DOI : 10.1016/j.matbio.2004.08.004

A. I. Su, T. Wiltshire, S. Batalov, H. Lapp, K. A. Ching et al., A gene atlas of the mouse and human protein-encoding transcriptomes, Proceedings of the National Academy of Sciences, vol.34, issue.3, pp.6062-6069, 2004.
DOI : 10.1038/ng1171

R. X. Sun, Z. Y. Lu, J. Wijdenes, J. Brochier, C. Hertog et al., Large scale and clinical grade purification of syndecan-1+ malignant plasma cells, Journal of Immunological Methods, vol.205, issue.1, pp.73-79, 1997.
DOI : 10.1016/S0022-1759(97)00056-2

M. Van-driel, U. Gunthert, A. C. Van-kessel, P. Joling, R. Stauder et al., CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells, Leukemia, vol.16, issue.1, pp.135-178, 2002.
DOI : 10.1038/sj.leu.2402336

Y. D. Wang, J. De-vos, M. Jourdan, G. Couderc, Z. Y. Lu et al., Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells, Oncogene, vol.21, issue.16, pp.2584-92, 2002.
DOI : 10.1038/sj.onc.1205355

J. Wijdenes, W. C. Vooijs, C. Clement, J. Post, F. Morard et al., A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1, British Journal of Haematology, vol.94, issue.2, pp.318-341, 1996.
DOI : 10.1046/j.1365-2141.1996.d01-1811.x

E. Erbb3, their specific ligands NRG1-2, and their co-receptor syndecan-1